Proteostasis Therapeutics to Present Data at Two Upcoming Scientific Meetings

October 10, 2012 5:16 PM ET

Cambridge, Mass., October 10, 2012 — Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan diseases, announced today that the Company will present data on its two lead programs at the upcoming 26th Annual North American Cystic Fibrosis Conference (NACFC) to be held in Orlando, FL on October 11-13, 2012 and the Society for Neuroscience (SfN) 42nd Annual Meeting to be held in New Orleans, LA on October 13-17, 2012. Proteostasis Therapeutics' scientists will make the following data presentations:

- **26th Annual North American Cystic Fibrosis Conference (NACFC)**: Poster presentation entitled "Small Molecule Regulators of the Proteostasis Network Enhance CFTR Protein Function" on Thursday, October 11, 2012 at 11:50 am ET in Hall B of the Orange County Convention Center.
- **Society for Neuroscience (SfN) 42nd Annual Meeting**: Nanosymposium presentation entitled "Proteolytic degradation and clearance of misfolded proteins associated with neurodegenerative diseases by small molecule inhibition of Usp14" on Wednesday, October 17, 2012 at 3:15 pm CT in Room 273 of the Ernest N. Morial Convention Center.

About Proteostasis Therapeutics

Proteostasis Therapeutics is developing disease-modifying therapeutics for orphan and neurodegenerative diseases. The Company's lead programs in Cystic Fibrosis (CF) and protein aggregation disorders such as Parkinson's disease modulate protein chaperone and proteasomal degradation pathways within the cell. These pathways are part of the cellular 'quality control' machinery, called the protein homeostasis network or Proteostasis Network (PN) that regulates protein folding, trafficking, and clearance. By enhancing the function and capacity of the PN, the Company's product candidates correct for imbalances in the PN resulting from the cumulative effects of disease, genetic mutations, environmental factors, and aging. For more information, please visit www.proteostasis.com.

Investor Contact:

Lilian Stern

Stern Investor Relations, Inc.

212-362-1200